Kedrion supports the 2020 European Hemophilia Consortium Conference

In the year of the COVID-19 pandemic, after supporting the Virtual Summit of the World Federation of Hemophilia (WFH) and the Congress of the International Society for Thrombosis and Hemostasis (ISTH), Kedrion Biopharma is proud to support the 2020 Conference of the European Hemophilia Consortium (EHC), which will be held remotely on October 5-9.

 A wide-ranging event featuring a rich and varied virtual format of scientific sessions, symposia, networking events and workshops that will stimulate the medical-scientific world to discuss and actively exchange experiences and expertise on key current issues in the treatment of hemophilia, such as pain management, the advent of new therapies, the treatment of patients with mild hemophilia and the increasingly prominent role played by education in a rapidly evolving therapeutic area.

The company's presence at the EHC Conference with a virtual booth is further evidence of our continued commitment to working with people living with rare diseases such as hemophilia. For this reason, over the last few years, Kedrion has been supporting the European Hemophilia Consortium in the PARTNERS project (the Procurement of Affordable Replacement Therapies – Network of European Relevant Stakeholders), an initiative aimed at improving access to treatments for coagulation disorders in European countries where the recommended minimum therapeutic standards still have not been reached.

For more information please contact: [email protected]